Kura Oncology Inc
Closed
SectorHealthcare
10.2 2.41
Overview
Share price change
24h
Min
9.86
Max
10.32
Income | 7.7M -73M |
|---|---|
Sales | 929K 18M |
EPS | -0.828 |
Profit margin | -401.495 |
Employees | 260 |
EBITDA | 7.4M -78M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +174.51% upside |
Next Earnings | 6 Aug 2026 |
|---|
Market Cap | 159M 1B |
|---|---|
Previous open | 7.79 |
Previous close | 10.2 |
Kura Oncology Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Kura Oncology Inc Forecast
Price Target
By TipRanks
174.51% upside
12 Months Forecast
Average 28.11 USD 174.51%
High 40 USD
Low 15 USD
Based on 11 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
